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Intracranial metastases from liposarcoma are rare and almost always preceded by the development of systemic tumour spread. We
report here a case of liposarcoma with spread to the cranial nervous system 23 years after treatment of the primary tumour. The
literature on brain metastases from soft tissue sarcoma is also reviewed.
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CASE REPORT
A 48-year old Caucasian female with active rheumatoid
arthritis was diagnosed with a low-grade myxoid liposar-
coma of the left thigh in 1981. This was treated with surgery
followed by radiotherapy. In 1991, she was discharged from
routine oncological followup. In 1998, she was rereferred
by her GP for investigation of a left groin mass. Biopsy
of the groin mass conﬁrmed recurrent liposarcoma and
restaging investigations conﬁrmed that the lesion was iso-
lated. Surgery and radiotherapy (5000Gy in 25 fractions)
were used to treat the recurrent liposarcoma. The pathol-
ogy report revealed that the tumour had transformed into
a “high-grade myxoid/round-cell liposarcoma surrounding
the iliac artery and vein, involving the deep resection mar-
gins.”
Over the next 6 years, the patient continued on close
outpatient followup with regular chest X rays. During this
time, persistent left leg oedema became problematic. In ad-
dition, her rheumatoid arthritis remained symptomatic de-
spite treatment with hydroxychloroquine, methotrexate, and
indomethacin.
In October 2004, the patient was admitted as a medical
emergency with a 5-day history of nausea and vomiting, se-
vere occipital headache, photophobia, and diplopia. In ad-
dition, she described a strange sensation in her tongue with
impaired tongue movement. On examination, a 3cm ×3cm
smooth mobile cervical neck node was noted in addition to
a left VI cranial nerve palsy, a right XII cranial nerve pals,
y and hypotonia of the left side of the tongue. A lumbar
puncture, CT brain, and blood tests including a vasculitic
screen and viral serology were normal. An MRI demon-
strated a “high signal at apex of the temporal bone” but was
otherwise normal. Over the next 10 days, the patient con-
tinued to complain of a persistent dull throbbing headache
and developed a right-sided VI nerve palsy. FNA of the
neck node conﬁrmed metastatic liposarcoma and a CT scan
of the chest/abdomen and pelvis revealed “widespread tu-
mour deposits in the right psoas muscle and pelvis.” The
lungs were clear of metastatic disease. A repeat MRI done
3 weeks following her admission this time showed that
“at the skull base, the clivus gives an abnormal marrow
signal with inﬁltration, most likely due to metastatic dis-
ease.” Due to intractable symptoms, she went on to re-
ceive palliative radiotherapy to the base of skull (30Gy in
10 fractions). A repeat CT scan done 6 weeks after the
last scan showed progressive disease in the abdomen and
pelvis with new lung metastases. Whilst waiting to com-
mence palliative chemotherapy, the patient developed neu-
rogenic dysphagia and died from aspiration pneumonia. At
postmortem, meningeal thickening was noted in the area of
the mid brain (Figure 1). Further neuropathological exam-
ination revealed liposarcoma cells within blood vessels in
the subarachnoid space (Figure 2) in addition to deposits
of metastatic liposarcoma in the subarachnoid space itself
(Figure 3).2 Sarcoma
Figure 1:Grosspostmortemimageofmidbrainshowingthickened
meninges.
Figure 2: Liposarcoma cells seen within a blood vessel in the sub-
arachnoid space.
DISCUSSION
Brain metastases from soft tissue sarcoma (STS) are rare, oc-
curring in 1–3% patients [1–3]. Autopsy series have demon-
strated a higher rate of occult intracerebral metastases rang-
ing from 3% to 16% [1, 2, 4]. When diagnosed in the symp-
tomatic patient, brain metastases are usually preceded by
pulmonary metastases [3].
Previous studies have identiﬁed leimyosarcoma, liposar-
coma, and malignant ﬁbrous histiocytoma (MFH) as the
subtypes of STS most likely to metastasize to the brain
[3]. Wronski et al in 1995 identiﬁed embryonal rhab-
domyosarcoma as the STS subtype most likely to spread
to the brain in his review of patients ranging in age
from 2.6t o6 8y e a r s[ 5]. Embryonal rhabdomyosarcoma
is the commonest STS amongst children and young adults
and this may explain the diﬀerence between these re-
ports.
In addition to the tumour subtype in STS, the site of
initial disease also appears inﬂuential in determining the
most likely sites of distant metastases. The ﬁrst site of dis-
tant metastasis for patients with extremity and trunk STS
is usually the lung with local recurrence rarely a problem
Figure 3: Liposarcoma in subarachnoid space.
in these patients [6, 7]. In contrast, patients with retroperi-
toneal and visceral STS, of the same histological type, tent
to recur locally rather than at distant sites. These patients
die of local failure rather than surviving long enough to
succumb to metastatic disease [8, 9]. Early surgical inter-
vention of isolated intracranial metastases prolongs disease-
free and overall survival [3, 10] and remains the standard
treatment. External beam radiotherapy oﬀers local control in
these patients but does not translate into increased survival
[10]. Chemotherapy for the treatment of STSBM (soft tis-
sue sarcoma brain metastases) has been disappointing with
the exception of an isolated report of complete remission of
brainmetastasesinonepatienttreatedwithDoxorubicinand
Dacarbazine [11]. Unfortunately, the other sites of visceral
disease in this patient failed to respond to this regimen.
This case describes the development of intracranial
metastases in a patient treated 23 years previously for a li-
posarcoma of the lower limb. Postmortem ﬁndings con-
ﬁrmed that this patient’s neurological signs and symptoms
were due to meningeal metastatic disease of the same his-
tological subtype as the original tumour. The brain metas-
tases became clinically apparent 23 years after treatment of
the initial primary. Such a long interval between treatment
of the primary tumour and CNS relapse has been described
elsewhere in patients with prolonged survival, either in as-
sociation with the STS having a long natural history or as
a result of extended disease-free survival from eﬀective local
treatment of the primary tumour [12, 13]. Others have de-
scribed an increase in CNS metastases in the setting of pro-
longed remission induced by chemotherapy [1, 12]. This pa-
tient did not receive chemotherapy as part of her treatment
as her brain metastases were only diagnosed at postmortem
and uncharacteristically were not preceded by the develop-
ment of pulmonary metastases.
ThiscaseillustratesthatSTScanrelapseintheCNSwith-
out the presence of widespread disseminated disease. CNS
relapse can occur many years after treatment of the primary
tumour and a high index of suspicion should be maintained
inanypatientwithanSTSpresentingwithneurologicalsigns
and symptoms. Early diagnosis and appropriate treatment of
selected patients with STSBM can improve survival.Michelle Ferguson et al 3
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